06938 IPO | REEBO BIO LISTED ON 9 JANUARY WITH A FIRST SUBSCRIPTION AMOUNT OF HK$11710.93

$ REEBO BIO-B (06938.HK) $ The announcement was made that the Company intends to offer approximately 27.4874 million shares worldwide in the IPO on December 31-January 6, which is expected to be listed on January 9, 2026.

About Reebo Biologics

Ribo Biologics is a biopharmaceutical company engaged in the research and development of micronucleic acid drugs, with a particular focus on siRNA therapeutics. Launched in 2007, the company is one of the pioneers in this field. The company's mission is to lead the way in developing new therapies to radically change the way we treat diseases that need to be addressed, including cardiovascular, metabolic, kidney and liver diseases. Backed by a strong portfolio of intellectual property rights in the global field of RNA interference (RNAi) technology, the company has built a technology platform for integrated autonomous development tailored to nucleic acid therapy for nearly two decades. Covering the entire drug development cycle from drug design, delivery, modification to CMC and production, these platforms lay a solid foundation for the company to develop potential first-of-its-kind and best-in-class micronucleic acid drugs.

CHAIBO BIOLOGIC IS BRINGING MICROKEROSENE THERAPY TO PATIENTS AROUND THE WORLD. Therefore, the company has created a global integrated pharmaceutical development system to achieve this goal of high quality and high efficiency. Led by a team of scientists with more than 20 years of experience in the development of nucleic acid and other pharmaceutical products and industry acumen, the company has obtained IND/CTA approval from major global market regulatory Institutions to shorten the week for elective drugs from spot selection to laboratory testing. ONLY IN 2024, THE COMPANY RECEIVED FIVE IND/CTA APPROVALS FROM ITS REGULATORY DEPARTMENTS, FOUR OF WHICH WERE INTERIM TRIALS. The company is rolling out in-patient trials in several countries around the world, including Europe, China and Australia, to accelerate drug development by leveraging regulatory frameworks in different regions.

Ribo bio financial overview

For the six months ended December 31, 2024 and June 30, 2025, the Swiss Biologics division generated RMB142.6 million, RMB66.3 million and RMB103.8 million, most of which came from the company's own licenses and cooperation agreements. For the years ended December 31, 2023 and the six months ended June 30, 2024 and June 30, 2025, the total operating support of the Company was RMB315.8 million, RMB280.4 million, RMB134.8 million and RMB129.1 million, respectively (Research 79.5%, 75.0%, 77.1%, and 71.0% of Open Support, and Sales and Distribution Support.

Uses of Ribo Biofunding

In terms of funding, Ribo Bio expects net proceeds from global sales of HK$1.474 billion (assuming no overallotment options are exercised at an offer price of HK$57.97). Pursuant to the offering, Ribo Biomics will use the global IPO for the following purposes:

Approximately 37.4% will be used for the development of the core product RBD4059 Approximately 19.6% will be used for the development of RBD5044. Approximately 15.9% will be used for the development of RBD1016. Approximately 10.1% will be used for the development of pipeline assets in the pre-bed application phase (including (i)SR122, one for the most common blood fat About 8.9% of the funds available for antilipid-lowering siRNA and II)RBD8088, a combination antipyretic drug used for neuroplasia, will be allocated to advanced companies that do not enter the pre-bed application testing phase About 8.1% of the company's technology platform to develop and strengthen its assets will be used for operating capital and other general corporate purposes.

Read more:Reebok Bio-B Prospectus

The New Stock Gold Season Has Arrived! Upcoming Share Futures, 0 Interest, 0 Operating Fees, 0 Cash Purchase. The opportunity to participate and participate in the event is exempt from 1 year of renewal fees,Come and experience it >>

Note: The event is limited to Hong Kong users.